PD-1/L1 Update: Roche’s Atezolizumab Advances, Merck’s Keytruda Strikes In New Tumors
This article was originally published in The Pink Sheet Daily
Executive Summary
European Cancer Congress featured the first detailed dataset for atezolizumab in lung cancer, long-term data for Bristol’s Opdivo in non-squamous NSCLC and Merck’s Keytruda in new tumor types.